PAVE 100

Phase:
IIb
Status:
Withdrawn
Strategies:
DNA, Viral Vector - Adeno
Candidates:
VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP
Countries:
USA
Volunteers:
0

A test-of-concept clinical trial to evaluate the efficacy, safety, and immunogenicity of a multiclade HIV-1 DNA plasmid vaccine, VRC-HIVDNA016-00-VP, followed by a multiclade recombinant adenoviral vector vaccine, VRC-HIVADV014-00-VP.